ExCellThera and Astellas enter into license for the use of molecule UM171 in the field of pluripotent stem cells

MONTREAL, July 13, 2021 – ExCellThera Inc. (ExCellThera), a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced that it has entered into a licensing agreement with Astellas Pharma Inc. through its US subsidiary, Astellas Institute for Regenerative Medicine, for the in vitro use of the UM171 compound and certain other molecules in the field of pluripotent stem cells (PSCs) and PSC-derived cells.

NewsGuest UserJuly 13, 2021ExCellThera, Astellas, licensing, agreement